ERAS (Erasca) 50-Day SMA: $13.56 (As of Jun. 29, 2026)


ERAS Erasca Inc ERAS
22 GF Score
Price $15.94
! 3 Warning Signs
View Full Analysis

What is Erasca 50-Day SMA?

Erasca ERAS +7.09% 22 50-Day SMA is $13.56 as of Jun. 29, 2026. GuruFocus rates ERAS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2026-06-29), Erasca's 50-Day SMA is $13.56. It's 20-Day SMA is $13.89 and 200-Day SMA is $8.89.

Erasca  (NAS:ERAS) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.

Erasca 50-Day SMA Related Terms

ERAS vs CELC, TNGX, DNTH: 50-Day SMA Comparison

For the Biotechnology subindustry, Erasca's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Erasca 50-Day SMA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Erasca's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Erasca's 50-Day SMA falls into.


ERAS
22GF Score
Erasca Inc ERAS
50-Day SMA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Erasca  (NAS:ERAS) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 50-Day SMA →
What does a 50-Day SMA of $13.56 mean?
Erasca (ERAS) has a 50-Day SMA of $13.56 as of Jun. 29, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Erasca and its competitors.
Is Erasca's 50-Day SMA too high?
Erasca's current 50-Day SMA is $13.56. Overall, Erasca has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Erasca's 50-Day SMA compare to CELC and TNGX?
Erasca's 50-Day SMA of $13.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Biotechnology company?
A good 50-Day SMA depends on the Biotechnology industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on Erasca and its competitors. Erasca's current 50-Day SMA is $13.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Erasca stock overvalued right now?
Erasca (ERAS) has a current 50-Day SMA of $13.56. The current 50-Day SMA is $13.56. Erasca's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For Erasca (ERAS), the current 50-Day SMA is $13.56 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Erasca Business Description

Address 3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
22GF Score

Get the complete analysis for ERAS

50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.94
Price